The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Open accessAbstract
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival. However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs). Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically. Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner, we searched for such vulnerabilities in CML LSCs. We performed metabolic analyses on both stem cell–enriched (CD34+ and CD34+CD38−) and differentiated (CD34−) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts. Through combination of stable isotope–assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metabolism for their survival. We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML. Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388
Cancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3483 · Cited by 1,324
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Self-citationSupporting aspartate biosynthesis is an essential function of respiration in proliferating cells
Sullivan, L. B., Gui, D. Y., Hosios, A. M., Bush, L. N., Freinkman, E., & Vander Heiden, M. G. (2015) · Cell · doi:10.1016/j.cell.2015.07.017 · Cited by 1,173
Simsek, T., Kocabas, F., Zheng, J., DeBerardinis, R. J., Mahmoud, A. I., Olson, E. N., Schneider, J. W., Zhang, C. C., & Sadek, H. A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.011 · Cited by 1,101
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Self-citation
Cited by
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A., & Higgins, G. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3070 · Cited by 1,135
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0291-9 · Cited by 645
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Yap, T. A., Daver, N., Mahendra, M., Zhang, J., Kamiya-Matsuoka, C., Meric-Bernstam, F., Kantarjian, H. M., Ravandi, F., Collins, M. E., Francesco, M. E. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02103-8 · Cited by 401
Improving the metabolic fidelity of cancer models with a physiological cell culture medium
Vande Voorde, J., Ackermann, T., Pfetzer, N., Sumpton, D., Mackay, G., Kalna, G., Nixon, C., Blyth, K., Gottlieb, E., & Tardito, S. (2019) · Science Advances · doi:10.1126/sciadv.aau7314 · Cited by 390
Self-citationAutophagy and cancer stem cells: molecular mechanisms and therapeutic applications
Nazio, F., Bordi, M., Cianfanelli, V., Locatelli, F., & Cecconi, F. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0292-y · Cited by 388
Mitochondrial ubiquinol oxidation is necessary for tumour growth
Martínez-Reyes, I., Cardona, L. R., Kong, H., Vasan, K., McElroy, G. S., Werner, M., Kihshen, H., Reczek, C. R., Weinberg, S. E., Gao, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2475-6 · Cited by 368
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St-Germain, J., Heese, L. E., Egan, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.014 · Cited by 349
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Self-citationMetabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
Insights into new mechanisms and models of cancer stem cell multidrug resistance
Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., & LLeonart, M. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.022 · Cited by 324
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy
Fendt, S.-M., Frezza, C., & Erez, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0844 · Cited by 313
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 304
Mitochondrial RNA modifications shape metabolic plasticity in metastasis
Delaunay, S., Pascual, G., Feng, B., Klann, K., Behm, M., Hotz-Wagenblatt, A., Richter, K., Zaoui, K., Herpel, E., Münch, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04898-5 · Cited by 303
Small-molecule inhibitors of human mitochondrial DNA transcription
Bonekamp, N. A., Peter, B., Hillen, H. S., Felser, A., Bergbrede, T., Choidas, A., Horn, M., Unger, A., Di Lucrezia, R., Atanassov, I., et al. (2020) · Nature · doi:10.1038/s41586-020-03048-z · Cited by 274
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Mitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 263
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
Mitochondria: The metabolic switch of cellular oncogenic transformation
Tan, Y. Q., Zhang, X., Zhang, S., Zhu, T., Garg, M., Lobie, P. E., & Pandey, V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188534 · Cited by 75
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01315-0 · Cited by 56
OXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59
T cell toxicity induced by tigecycline binding to the mitochondrial ribosome
Shao, Q., Khawaja, A., Nguyen, M. D., Singh, V., Zhang, J., Liu, Y., Nordin, J., Adori, M., Axel Innis, C., Castro Dopico, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59388-9 · Cited by 16
In situ metabolic Characterisation of Breast Cancer and its Potential Impact on Therapy
Petővári, G., Dankó, T., Tőkés, A.-M., Vetlényi, E., Krencz, I., Raffay, R., Hajdu, M., Sztankovics, D., Németh, K., Vellai-Takács, K., et al. (2020) · Cancers · doi:10.3390/cancers12092492 · Cited by 16
Exploring and bypassing resistance to targeted therapies in colorectal cancer
Favier, S., Xiong, W., Chalabi-Dchar, M., Chettab, K., Piercey, O., Wu, T., Fenouil, T., Albaret, M.-A., Jordheim, L. P., Diaz, J.-J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118741 · Cited by 12
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells
Shah, M., Kumar, H., Qiu, S., Li, H., Harris, M., He, J., Abraham, A., Crossman, D. K., Paterson, A., Welner, R. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157421 · Cited by 11
Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells
Patel, S. B., Kuznetsova, V., Matkins, V. R., Franceski, A. M., Bassal, M. A., & Welner, R. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.001 · Cited by 7
Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells
Xia, L., Liu, J.-Y., Yang, M.-Y., Zhang, X.-H., Jiang, Y., Yin, Q.-Q., Luo, C.-H., Liu, H.-C., Kang, Z.-J., Zhang, C.-T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1632 · Cited by 5
Metadata
- Authors
- Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E.
- Venue
- Nature Medicine
- Published
- 2017-09-18
- Volume
- 23
- Issue
- 10
- Pages
- 1234-1240
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2755975022
- Cited by
- 546
- References
- 25
- FWCI
- 29.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.